Gogikar Amaresh, Nanda Ankita, Janga Lakshmi Sai Niharika, Sambe Hembashima G, Yasir Mohamed, Man Ruzhual K, Mohammed Lubna
Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2023 Sep 3;15(9):e44624. doi: 10.7759/cureus.44624. eCollection 2023 Sep.
Heart failure (HF) is a notable public health issue, and intravenous loop diuretics are frequently employed to address acute decompensated heart failure (ADHF) and alleviate symptoms of congestion. However, prolonged use of loop diuretics can lead to drug resistance, and some patients experience refractory volume overload that does not respond to treatment. Sequential nephron blockade, which involves combining loop and thiazide diuretics, has been proposed as a strategy to overcome diuretic resistance and improve fluid overload management. This systematic review aims to critically evaluate the effectiveness and safety of this combination diuretic therapy. Following the directives detailed in the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted. Eligibility criteria were established to select relevant studies, including the requirement for studies to be conducted on human subjects and published as free full-text papers in English within the last 10 years. Several databases were searched using a combination of Medical Subject Heading (MeSH) phrases and keywords related to heart failure, loop diuretics, and thiazide diuretics. The search yielded 948 references, and after screening titles, abstracts, and full-text papers, eight final studies (five observational studies and three randomized control trials) were included in the review. Based on the findings of this systematic review, there is substantial evidence to endorse the efficacy of combination diuretic therapy of loop and thiazide diuretics in augmenting diuresis and enhancing outcomes for patients who exhibit insufficient responses to single-agent diuretics. Additionally, the review provides valuable insights about the timing and type of diuretics to use, helping clinicians make informed therapeutic decisions. However, to ensure patient safety and well-being, it is imperative to take into account the potential for electrolyte disturbances and impacts on renal function, necessitating diligent and vigilant monitoring as well as effective management strategies. In light of these findings, further research is warranted to optimize the dosing regimens and to delve deeper into the long-term safety and efficacy of combination therapy. Such research endeavors will undoubtedly contribute to refining treatment approaches and advancing patient care in the field of HF management.
心力衰竭(HF)是一个显著的公共卫生问题,静脉注射袢利尿剂经常用于治疗急性失代偿性心力衰竭(ADHF)并缓解充血症状。然而,长期使用袢利尿剂会导致耐药性,一些患者会出现难治性容量超负荷,对治疗无反应。序贯肾单位阻滞,即联合使用袢利尿剂和噻嗪类利尿剂,已被提出作为克服利尿剂耐药性和改善液体超负荷管理的一种策略。本系统评价旨在严格评估这种联合利尿剂治疗的有效性和安全性。按照《2020年系统评价和Meta分析优先报告项目》(PRISMA)指南中详述的指令进行了全面检索。制定了纳入标准以选择相关研究,包括要求研究针对人类受试者开展,并在过去10年内以英文全文发表。使用与心力衰竭、袢利尿剂和噻嗪类利尿剂相关的医学主题词(MeSH)短语和关键词组合检索了多个数据库。检索得到948篇参考文献,在筛选标题、摘要和全文后,本评价纳入了8项最终研究(5项观察性研究和3项随机对照试验)。基于本系统评价的结果,有充分证据支持袢利尿剂和噻嗪类利尿剂联合利尿剂治疗在增加尿量和改善对单药利尿剂反应不足的患者结局方面的疗效。此外,该评价提供了关于利尿剂使用时机和类型的宝贵见解,有助于临床医生做出明智的治疗决策。然而,为确保患者安全和健康,必须考虑到电解质紊乱的可能性及其对肾功能的影响,需要进行勤勉且警惕的监测以及有效的管理策略。鉴于这些发现,有必要进一步开展研究以优化给药方案,并更深入地探究联合治疗的长期安全性和疗效。此类研究努力无疑将有助于完善治疗方法并推动心力衰竭管理领域的患者护理进展。